If other treatments for chronic conditions such as those listed above have not reached your goals, LDN treatments may have more to offer. LDN affects the central nervous system differently compared to most pain medication, and therefore offers results beyond what other treatments can achieve. LDN enhances your body's own endorphin response and directly reduces the production of chemicals that inflame nerves. The enhancement of the body's own endorphin response is part of what makes LDN effective for depression, PTSD, and anxiety as well. If you struggle with chronic pain or other conditions listed here, please contact The Taub Group now to schedule an evaluation.
Naltrexone is an inexpensive, generic drug more commonly used to moderate withdrawal symptoms. However, 21st-century research is showing that very low doses of naltrexone increase the body's production of endorphins and make the body more responsive to those endorphins. Additionally, LDN influences glial cells to stop producing chemicals that inflame nerves. This nerve inflammation is thought to be a component in the chronic pain cycle. More traditional pain meds work by quieting the nerve fibers themselves. For some people, more is needed.
A big advantage is that naltrexone is not an opiate. In fact, it is the opposite of an opiate. Naltrexone is an opiate-blocking drug. It is FDA-approved. LDN is not generally considered addictive. For some people, discontinuing LDN may be like quitting caffeine. Complaints involve headaches, concentration, and low energy for a few days. It may be okay to take LDN with other meds you are taking, and it may not. In consultation, we will be able to tell you if you should discontinue one or more of your current meds to use LDN.
Please note that the results of medical treatments vary from person to person. Most medical treatments have a certain percentage of non-responders. At The Taub Group in Charlotte North Carolina, low-dose naltrexone treatments (LDN) has been one approach we have used for years. As leaders in the management of treatment-resistant conditions, we have conducted original research on low-dose naltrexone treatment (a National-Clinical-Trial-registered, randomized, double-blinded, controlled trial). Even in cases that have been resistant to other treatments, we have found LDN to be highly effective in the treatment of fibromyalgia, rheumatoid arthritis, Sjogren's syndrome, ulcerative colitis, chronic fatigue syndrome, and autoimmune disorders.
Low-dose naltrexone increases the release of endorphins and lowers inflammation in the central nervous system. Inflammation of the central nervous system is believed to contribute to the chronic nature of some pain syndromes. Repeated or constant pain signals can trigger glial cells to release inflammatory chemicals that affect nerves. The resulting inflammation makes the central nervous system hypersensitive to pain. Traditional approaches to chronic pain have attempted to break this pain cycle by quieting pain signals from the nerves.
The traditional approach has sometimes involved opioid medications and their known dangers. Low-dose naltrexone works differently. Rather than quieting the nerve fibers, LDN affects the glial cells directly, influencing them to stop releasing the inflammatory chemicals. Reducing the inflammation helps the central nervous system return to normal function.
When pain syndromes have overlay with behavioral health challenges such as depression, anxiety, or PTSD, low-dose naltrexone provides additional advantages. By boosting the body's reaction to its own endorphins, this treatment protocol can upregulate mood as well.